糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性

doi:10.6040/j.issn.1671-7554.0.2016.1681

摘要/Abstract

摘要： 目的观察骨代谢在糖皮质激素性骨质疏松症(GIOP)进展过程中与糖皮质激素用药时间的关系及变化规律,并依据骨代谢变化趋势探讨GIOP的防治策略。方法检测应用GC控制病情的系统红斑狼疮患者117例和健康人群21例骨代谢标志物(β-CTX、T-P1NT、N-MIDOs),测定L1-4椎体骨密度。依据GC使用时间将患者分为7个亚组:Ⅰ组用药1~6个月,Ⅱ组用药7~12个月,Ⅲ组用药13~18个月,Ⅳ组用药19~24个月,Ⅴ组用药25~30个月,Ⅵ组用药31~36个月,Ⅶ组用药>36个月。结果 Ⅰ组、Ⅱ组和Ⅲ组β-CTX较正常对照组明显升高,差异有统计学意义(P<0.05);Ⅵ组和Ⅶ组β-CTX较正常对照组明显减低,差异有统计学意义(P<0.05);Ⅳ组和Ⅴ组β-CTX较正常对照组无明显差异(P>0.05);应用GC的各亚组T-P1NT、N-MIDOs均较正常对照组明显减低,差异有统计学意义(P<0.05);Ⅱ~Ⅶ组骨密度较正常对照组明显减低,差异有统计学意义(P<0.05)。结论 GIOP形成过程中,骨代谢是由高分解状态向低分解低成骨低转换状态转变。应用GC 1~18个月的SLE患者骨代谢状态处于高分解低成骨,应用GC 30个月以上的患者骨代谢状态处于低分解低成骨低转换状态。

关键词: 糖皮质激素性骨质疏松症, 系统性红斑狼疮, 糖皮质激素, 骨代谢标志物, 骨密度

Abstract: Objective To investigate the changes of bone metabolism in different durations of glucocorticoid(GC)treatment of systemtic lupus erythematosus(SLE), and to explore the therapeutic schedule of glucocorticoid-induced osteoporosis(GIOP). Methods A total of 117 pre-menopausal women with SLE were involved as the observation group and 21 healthy pre-menopausal women served as the control group. According to the duration of GC therapy, the patients were divided into 7 subgroups: group Ⅰ(medication for 1~6 months), group Ⅱ(medication for 7~12 months), group Ⅲ(medication for 13~18 months), group Ⅳ(medication for 19~24 months), group Ⅴ(medication for 25~30 months), group Ⅵ(medication for 31~36 months), and group Ⅶ(medication for >36 months). The contents of amino-terminal-propeptide of type I collagen(T-PINT), amino-terminal of osteocalcin(N-MIDOs), type I collagen cross-linked C-telopeptide degradation fragments(β-CTX)and bone mineral density(BMD)of all subjects were measured. Results The serum β-CTX level was significantly elevated in group Ⅰ, Ⅱ and Ⅲ, and remark- 山东大学学报 (医学版)55卷5期 -徐大霞,等.糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性 \=-ably reduced in group Ⅵ and Ⅶ compared with the control group(P<0.05), while there was no difference in group Ⅳ and V(P>0.05). The serum levels of T-PINT and N-MIDOs in all subgroups were significantly lower than those in the control group(P<0.05). The BMD of patients receiving more than 6-month GC therapy was significantly lower than that of healthy controls(P<0.05). Conclusion In conclusion, the change of bone metabolism is from high decomposition to low decomposition and low osteogenesis in the process of GIOP formation. In the first 18 months of GC therapy, bone metabolism is in the state of low osteogenesis and high decomposition; after 30 months, it is in the state of low osteogenesis and low decomposition.

Key words: Glucocorticoid-induced osteoporosis, Systemic lupus erythematosus Glucocorticoid, Bone metabolism, Bone mineral density

中图分类号:

R593.24

徐大霞,侯楠,李晓峰,王闯,孔猛,焦广俊,陈允震. 糖皮质激素性骨质疏松症骨代谢与糖皮质激素用药时间的相关性[J]. 山东大学学报（医学版）, 2017, 55(5): 103-107.

XU Daxia, HOU Nan, LI Xiaofeng, WANG Chuang, KONG Meng, JIAO Guangjun, CHEN Yunzhen. Relevance between bone metabolism of glucocorticoid-induced osteoporosis and duration of glucocorticoid treatment[J]. JOURNAL OF SHANDONG UNIVERSITY (HEALTH SCIENCES), 2017, 55(5): 103-107.

参考文献

[1] Weinstein RS.Glucocorticoid-induced Osteoporosis and Osteonecrosis[J].Endocrine Metab Clin North Am, 2012, 41(3):595-611.
[2] Rizzoli R, Adachi JD, Cooper C, et al.Management of glucocorticoid-induced Osteoporosis[J].Calcif TIssue Int, 2012, 91(4):225-243.
[3] 郭惠芳,高丽霞.2014年风湿免疫病学主要临床进展[J].临床荟萃, 2015, 30(2): 167-173.
[4] Grossman JM, Gordon R, Ranganath VK, et al. American College of Rheumatology 2010 recommendations for the prevention and treatment of glucocorticoid-induced Osteoporosis[J].Arthritis Care Res, 2010, 62(11):1515-1526.
[5] Lekamwasam S, Adachi JD, Agnusdei D, et al.A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis[J].Osteoporos Int, 2012, 23(9):2257-2276.
[6] Zimlichman E, Rothschild J, Shoenfeld Y, et al. Good prognosis for hospitalized SLE patients with non-related disease[J]. Autoimmun Rev, 2014, 13(11): 1090-1093.
[7] Weinstein RS. Clinical practice:Glucocorticoid-induced bone disease[J]. N Engl J Med, 2011, 36(5): 62-70.
[8] Kearns AE, Khosla S, Kostenuik PJ. Receptor activatior of nuclear factor kappaB ligand and oateoprotegerin regulation of bone remodeling in health and disease[J]. Endcor Rev, 2008, 29(2):155-192.
[9] Gifre L, Mongegal A, Peris P, et al.Effect of glucocorticoid treatment on Wnt signalling antagonists(sclerostin and Dkk-1)and their relationship with bone turnover[J]. Bone, 2013, 57(1): 272-276.
[10] Shusuke U, Toru I. Osteocytic cell necrosis is caused by a combination of glucocorticoid-induced Dickkopf-1 and hypoxia[J]. Med Mol Morphol, 2015, 48(2): 69-75.
[11] Qiang YW, Chen Y, Stepens O, et al. Myeloma-derived Dickkopf-1 disrupts Wnt-regulated osteoprotegerin and RANKL production by osteoblasts: a potential mechanism underlying osteolytic bone lesions in multiple myeloma[J]. Blood, 2008, 112(1): 196-207.
[12] Humphrey EL, Williams JH, Davie MW, et al. Effects of dissociated glucocorticoid on OPG and RANKL in osteoblastic cells[J]. Bone, 2006, 38(5): 652-661.
[13] Canalis E, Delany AM. Mechanisms of glucocorticoid action in bone[J]. Ann NY Acad Sci, 2002, 6(966): 73-81.
[14] Robert RC. Mechanisms of impaired growth: effect of steroids on bone and cartilage[J]. Horm Res, 2009, 72(1): 30-35.
[15] 刘海春,张剑锋,陈允震.骨质疏松大鼠股骨生物力学特性与骨胶原质量变化的相关研究[J].山东大学学报(医学版),2009, 47(5): 42-46. LIU Haichun, ZHANG Jianfeng, CHEN Yunzhen. Bone collagen and biomechanical propertyies in the femur of osteoporosis rats[J]. Journal of Shandong University(Health Sciences), 2009, 47(5): 42-46.
[16] Den Uyl D, Bultink IE, Lems WF. Adwances in glucocorticoid-induced osteoporosis[J]. Curr Rheumatol Rep, 2011, 13(3): 233-240.
[17] Seibel MJ, Cooper MS, Zhou H. glucocorticoid-induced osteoporosis: mechanisms,management, and future perspectives[J]. Lancet Diabetes Endocrinol, 2013, 1(1): 59-70.
[18] Reid DM, Devogelaer JP, Saag K, et al. Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis(HORIZON): a multicentre,double-blind, double-dummy, randomised controlled trial[J]. Lancet, 2009, 373(9671): 1253-1263.
[19] Saag KG, Shane E, Boonen S, et al. Teriparatide or alendronate in glucocorticoid-induced osteoporosis[J]. N Engl J Med. 2007, 357(20): 2028-2039.

相关文章 15

[1]	康随芳,王迎雪,张琪晨,王志仑,尹哲,肖娟,陈国玲. 系统性红斑狼疮患者睑板腺形态和功能的异常及其对泪膜的影响[J]. 山东大学学报 (医学版), 2024, 62(6): 65-70.
[2]	张迪,聂辰宇,刘继东,侯新国,陈丽. 常染色体显性遗传骨硬化症Ⅱ型的2例家系报道及文献复习[J]. 山东大学学报 (医学版), 2024, 62(6): 82-90.
[3]	郭浩男,周鹏,李小磊,岳涛,徐婧,邵长秀,贺青卿,庄大勇. 甲状旁腺全切术与甲状旁腺全切术+微量自体移植术治疗继发性甲状旁腺功能亢进的疗效对照[J]. 山东大学学报 (医学版), 2024, 62(12): 72-81.
[4]	杨庆婵,王咏梅,王承志. 急性纤维素性机化性肺炎3例病理特征及文献复习[J]. 山东大学学报 (医学版), 2023, 61(6): 58-64.
[5]	徐洪波,胡仁琴,田茂强,冉潇,陈艳. PIK3CD基因杂合突变所致新表型——系统性红斑狼疮[J]. 山东大学学报 (医学版), 2023, 61(1): 113-117.
[6]	成晅,杨帆,潘正论. 系统性红斑狼疮、抗磷脂抗体综合征伴颅内静脉窦血栓形成1例并文献复习[J]. 山东大学学报 (医学版), 2022, 60(6): 70-74.
[7]	王洲洋,江蓓,李宪花,甄军晖,杨向东,胡昭,刘广义,裴斐. 感染性心内膜炎、急性肾损伤伴PR3-ANCA阳性患者1例报道[J]. 山东大学学报 (医学版), 2022, 60(2): 60-64.
[8]	孔林笑语,孙书珍,余丽春,贾梦文. 188例儿童系统性红斑狼疮5年生存率及预后分析[J]. 山东大学学报 (医学版), 2022, 60(12): 69-76.
[9]	国云飞,舒强. 免疫抑制剂在风湿病相关复发性流产中的应用[J]. 山东大学学报 (医学版), 2021, 59(8): 38-43.
[10]	陈诗鸿. 糖皮质激素性骨质疏松症研究进展[J]. 山东大学学报 (医学版), 2021, 59(6): 33-37.
[11]	杜娇娇,庄向华,陈诗鸿,王雪萌,姜冬青,吴菲,韩晓琳,华梦羽,宋玉文. 绝经后骨质疏松症患者血清IL-31、IL-33表达变化[J]. 山东大学学报 (医学版), 2021, 59(6): 45-50.
[12]	康成为,刘雷,蒲小兵,谭钢,董长超,晏兆魁. 合并亚临床型甲状腺功能减退的骨质疏松症62例患者骨代谢及骨转换标志物水平分析[J]. 山东大学学报 (医学版), 2020, 58(5): 82-86.
[13]	王百惠,宋艳君,张帅庆,左秀丽,王青,张爱军,李如源. 以腹泻为首发症状的淀粉样变3例及文献复习[J]. 山东大学学报 (医学版), 2020, 58(5): 93-97.
[14]	李娜,张志勉. 138例39~81岁体检人员血管钙化指标的关联分析[J]. 山东大学学报 (医学版), 2020, 58(2): 85-89.
[15]	冯洒然,刘倩,王焱,李红,毕可红,朱传升. 系统性红斑狼疮伴发肝脾γδT细胞淋巴瘤1例并文献复习[J]. 山东大学学报 (医学版), 2018, 56(6): 87-90.

多维度评价

Viewed

Full text

Abstract

Cited

Shared

Discussed